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Inhibition of MUC1 biosynthesis via threonyl-tRNA
synthetase suppresses pancreatic cancer cell migration
Seung Jae Jeong1,2, Jong Hyun Kim1, Beom Jin Lim3, Ina Yoon1,2, Ji-Ae Song1, Hee-sun Moon1, Doyeun Kim1,
Dong Ki Lee4 and Sunghoon Kim1,2
Mucin1 (MUC1), a heterodimeric oncoprotein, containing tandem repeat structures with a high proportion of threonine, is
aberrantly overexpressed in many human cancers including pancreatic cancer. Since the overall survival rate of pancreatic
cancer patients has remained low for several decades, novel therapeutic approaches are highly needed. Intestinal mucin has
been known to be affected by dietary threonine supply since de novo synthesis of mucin proteins is sensitive to luminal
threonine concentration. However, it is unknown whether biosynthesis of MUC1 is regulated by threonine in human cancers. In
this study, data provided suggests that threonine starvation reduces the level of MUC1 and inhibits the migration of MUC1-
expressing pancreatic cancer cells. Interestingly, knockdown of threonyl-tRNA synthetase (TRS), an enzyme that catalyzes the
ligation of threonine to its cognate tRNA, also suppresses MUC1 levels but not mRNA levels. The inhibitors of TRS decrease the
level of MUC1 protein and prohibit the migration of MUC1-expressing pancreatic cancer cells. In addition, a positive correlation
between TRS and MUC1 levels is observed in human pancreatic cancer cells. Concurrent with these results, the bioinformatics
data indicate that co-expression of both TRS and MUC1 is correlated with the poor survival of pancreatic cancer patients. Taken
together, these ﬁndings suggest a role for TRS in controlling MUC1-mediated cancer cell migration and provide insight into
targeting TRS as a novel therapeutic approach to pancreatic cancer treatment.
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INTRODUCTION
Pancreatic cancer is one of the most aggressive human cancers.
The lack of early diagnoses and effective treatment strategies
are critical factors that can lead to rapid death and low survival
rates of pancreatic cancer patients.1 Even after surgical resec-
tion with curative intent, the prognosis is very poor due to the
high rate of metastasis.2 Hence, new strategies to ﬁnd a novel
therapeutic target are required to improve the treatment of
pancreatic cancer.3
MUC1, a member of the mucin family and a heterogeneous
glycoprotein, is normally expressed at the apical surface of
polarized epithelial cells of the mammary gland, stomach,
duodenum, pancreas, uterus, prostate and lungs.4 In malig-
nancy, MUC1 is overexpressed and repositioned over the entire
cell membrane of carcinoma cells and contributes to neoplastic
transformation, tumor survival, angiogenesis, and metastasis.5
Additionally, the cytoplasmic tail of MUC1 (MUC1-CT)
mediates intracellular signaling functions associated with
cancer cell survival and metastasis.6 Aberrant overexpression
of MUC1 is found in most human carcinomas including
pancreatic cancer7 and often used as a diagnostic marker for
metastatic progression.8
Mucins have a central backbone rich in threonine, proline,
and serine residues that account for 20–55% of the total amino
acid composition,9 with threonine alone constituting 28–35%
of the total amino acids.10 In comparison with other essential
amino acids, threonine is particularly important for the
maintenance of the gut and a large proportion of threonine
is retained in the intestines of piglets and humans.11,12
Although previous reports have shown that mucin synthesis
is sensitive to dietary threonine supply in the intestines of rats,
pigs, piglets and mice,13–17 it is unknown whether mucins are
affected by threonine in human cancer cells.
In this study, it is discovered that the levels of MUC1 are
affected by threonine in human pancreatic cancer cells. The
data presented has identiﬁed that the protein level of MUC1 is
also affected by threonyl tRNA synthetase (TRS), which is one
of the aminoacyl tRNA synthetases (ARSs), an essential enzyme
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transferring threonine to cognate tRNA for protein synthesis.18
In addition, it is demonstrated that TRS affects the migration of
pancreatic cancer cells through MUC1 biosynthesis. Moreover,
it appears that the expression of both TRS and MUC1 was
positively correlated in pancreatic cancer cells, as well as
associated with overall survival in the pancreatic cancer patients
of the cancer genome atlas (TCGA) data set.
MATERIALS AND METHODS
Materials
Anti-MUC1 (cat# ab109185) was purchased from Abcam (Cambridge,
UK), anti-MUC1 (cat# sc-7313), anti-ThrRS (cat# sc-166146), anti-c-
Myc (cat# sc-40), and anti-AlaRS (cat# sc-98547) were purchased from
Santa Cruz Biotechnology (Dallas, TX, USA), anti-alpha-tubulin (cat#
T6074) was purchased from Sigma-Aldrich (St Louis, MO, USA), and
anti-puromycin (cat# MABE343) was purchased from Millipore (Bill-
erica, MA, USA). L-[35S]-Methionine (Met) (cat# NEG709A) was
purchased from PerkinElmer (Waltham, MA, USA). Threonine, L-[3-
3H] (cat# ART0330) was purchased from American Radiolabeled
Chemicals (Saint Louis, MO, USA). Borrelidin (cat# ab144212) was
purchased from Abcam. 5′-O-(N-(L-threonyl)-sulfamoyl) adenosine
was purchased from Integrated DNA Technologies (Coralville, IA,
USA). Lipofectamine 2000 (cat# 11668030) and puromycin (cat#
A1113802) were purchased from Thermo Fisher (Waltham, MA, USA).
Cell culture
PANC-1, MIA PaCa-2 and HEK293T cells were cultured in high
glucose Dulbecco’s Modiﬁed Eagle’s Medium (HyClone, Logan, UT,
USA) supplemented with 10% fetal bovine serum (FBS) (HyClone)
and 1% streptomycin and penicillin (S/P) (HyClone). AsPC-1, Panc
10.05 and BxPC-3 cells were cultured in Roswell Park Memorial
Institute 1640 (HyClone) medium supplemented with 10% FBS and
1% S/P. HPAF-II cells were cultured in Eagle’s Minimum Essential
Medium (HyClone) with 10% FBS and 1% S/P. CFPAC-1 cells were
cultured in Iscove’s Modiﬁed Dulbecco’s Medium (HyClone) supple-
mented with 10% FBS and 1% S/P. Cells were incubated in a
humidiﬁed atmosphere at 37 °C in 5% carbon dioxide (CO2).
Threonine starvation of cells
For threonine depletion, cells were rinsed twice with threonine-free
medium (WelGENE, Daegu, Korea), and then incubated in threonine-
free medium for the indicated times. For wound-healing assays, cells
were rinsed with threonine-free medium twice and then incubated for
the indicated times in threonine-free medium containing dialyzed FBS
(Hyclone) after making scratches.
Preparation of cell lysates and immunoblotting
Cells were dissolved in lysis buffer containing 1% Triton X-100,
50 mM HEPES (pH 7.4), 2 mM EDTA, 10 mM pyrophosphate, 10 mM
glycerophosphate, and protease inhibitor cocktail (Calbiochem, San
Diego, CA, USA), and lysates were centrifuged at 13 000 r.p.m. for
15 min. Then, 20 μg of the extracted proteins were fractionated by
SDS–PAGE. Immunoblotting was performed according to previously
described methods using the speciﬁed antibodies.19
Quantitative real-time PCR
Total RNA was extracted from cells using the RNeasy Kit (QIAGEN,
Hilden, Germany) according to the manufacturer’s instructions and
the puriﬁed RNAs were used for cDNA synthesis using a PrimeScript
RT reagent kit (TaKaRa, Shiga, Japan). Quantitative polymerase chain
reaction (PCR) was performed using gene-speciﬁc primer sets and
SYBR Green Supermix (Bio-Rad, Hercules, CA, USA). Real-time PCR
was carried out in a 7500 real-time PCR system (Applied Biosystems,
Foster city, CA, USA) according to the manufacturer’s instructions.
Data were normalized against β-actin mRNA levels. Relative expres-
sion was calculated using the ΔΔCT method. PCR was performed
using the human MUC1 primer set (forward primer: 5′-GAACTA
CGGGCAGCTGGACATC-3′, reverse primer: 5′-GCTCTCTGGGCC
AGTCCTCCTG-3′), the human TRS primer set (forward primer: 5′-
GTAAGCCATGATGGTG-3′, reverse primer: 5′-CTGCCTGTTTG
CTGCGG-3′) and the β-actin primer set (forward primer: 5′-
GAGCTGCCTGACGGCCAGG-3′, reverse primer: 5′-CATCTGCTGG
AAGGTGGAC-3′).
[35S]-Met incorporation assay
Cells were seeded into 24-well plates, grown until subconﬂuence and
incubated in Met-free media containing 10 μCi ml− 1 [35S]-Met for
1 h. The cells were then washed twice with ice-cold PBS, treated with
5% trichloroacetic acid (TCA) for 30 min, washed twice with ice-cold
PBS and solubilized in 0.5 N NaOH. An aliquot was analyzed with a
liquid scintillation counter (Beckman Coulter, Brea, CA, USA).
Wound-healing assay
Wound-healing assays were performed with the IncuCyte Zoom
according to the supplier’s protocols. Cells were seeded in 96-well
ImageLock plates (Essen BioScience) and grown to 90–95% con-
ﬂuency. Subsequently, a WoundMaker (Essen Bioscience) was used to
create scratches in all of the wells, after the media was replaced. Images
of cell migration were recorded every 2 h for a total duration of 48 h
with the IncuCyte Kinetic Live Cell Imaging System and analyzed with
the IncuCyte Zoom software.
Cell proliferation analysis
Cells were seeded in triplicate using a 96-well plate at a density of 5000
cells per well and placed within a microplate tray on the IncuCyte
ZOOM (Essen BioScience, Ann Arbor, MI, USA). Cells were
monitored every 2 h for a total duration of 72 h using the IncuCyte
Kinetic Live Cell Imaging System (Essen BioScience) and analyzed
with the IncuCyte Zoom software (Essen BioScience).
RNA interference
Cells were transfected with duplex siRNA using the Lipofectamine 2000
transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. ON-TARGETplus SMARTpool siRNAs
against TRS (cat# L-011789) and AlaRS (cat# L-011565) were purchased
from GE Healthcare Dharmacon (Lafayette, CO, USA). A non-targeting
siRNA was used as a control (Dharmacon). Double-stranded siRNAs
targeting human TRS (5′-TCGCTTTCGGGTTCTCTCATCGCTT-3′) and
MUC1 (5′-GGUAAUGGUGGCAGCAGCCUCUCUU-3′) were purchased
from Invitrogen. Cells were incubated with the siRNA for 36−72 h.
Puromycin incorporation assay
Surface sensing of translation (SUnSET) was performed as previously
described.20 Brieﬂy, cells were incubated with 1 μM puromycin
(Thermo Fisher) for 30 min followed by washing with ice cold PBS
and lysing with lysis buffer. Cell lysates were loaded onto SDS–PAGE,
and western blotting was performed with a mouse anti-puromycin
monoclonal antibody (Millipore), and normalized against Ponceau S
staining (INtRON, Gyeongggi-do, Korea).
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Figure 1 MUC1 protein levels in pancreatic cancer cells after threonine deprivation. (a) Panc 10.05 cells were maintained in DMEM (AA+)
or were deprived of all amino acids (AA− ), phenylalanine (Phe− ), Threonine (Thr− ), Valine (Val− ) or Tryptophan (Trp− ) for 2 h. MUC1
and MUC1-CT protein levels were evaluated by immunoblotting (left) and are displayed relative to tubulin levels as a bar graph (right).
(b) The effects of amino acid deprivation on MUC1 transcription were evaluated by quantitative RT-PCR analysis in Panc 10.05 cells. (c)
Panc 10.05 cells were deprived of threonine (Thr− ) for 1 to 4 h. MUC1 and MUC1-CT protein levels were evaluated by immunoblotting
(left) and are displayed relative to tubulin levels as a bar graph (right). (d) The effects of threonine starvation on MUC1 transcription were
evaluated by qRT–PCR analysis in Panc 10.05 cells. (e) Panc 10.05 cells were incubated with [35S]-Met with or without threonine for the
indicated times. Protein synthesis was monitored by [35S]-Met incorporation assay and displayed as a bar graph. (f) Panc 10.05 cells were
cultured in media containing (AA+) or lacking threonine (Thr− ) for 2 h. After withdrawal for 2 h, threonine-containing media was added for
1 or 2 h (Thr− /+ or Thr− /++). MUC1 and MUC1-CT protein levels were evaluated by immunoblotting (left) and are displayed as a bar
graph (right). (g) Panc 10.05 cells were treated with 60 μg ml−1 cycloheximide (CHX) for 1 to 4 h and protein levels of MUC1 and
MUC1-CT levels were evaluated by immunoblotting with anti-MUC1 antibody (left) and displayed as a bar graph (right). (h) Immunoblotting
analysis of the MUC1 and MUC1-CT in lysates of AsPC-1 and BxPC-3 cells that were deprived threonine (Thr− ) for 2 to 4 h. (a–g)
*Po0.05; **Po0.01; ***Po0.001; ****Po0.0001; NS, not signiﬁcant vs control group. Values represent means± s.e.m. of three
independent experiments.
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Aminoacylation assay
Aminoacylation assays were performed as previously described.21
Brieﬂy, assays were carried out in a buffer containing 4 mM DTT,
50 mM HEPES-KOH (pH 7.6), 20 mM KCl, 10 mM MgCl2, 5 mM ATP,
2 mg ml− 1 yeast tRNA (Roche, Indianapolis, IN, USA), threonine,
L-[3-3H] (American Radiolabeled Chemicals), and cell lysates. Reac-
tions were initiated with cell lysates and conducted at 37 °C. Aliquots
(20 μl) were taken from the reactants after 30 min and quenched on
Whatman ﬁlter pads that were presoaked with 5% TCA. Pads were
washed three times for 10 min each time with cold 5% TCA, and once
with cold 100% ethanol. Washed pads were then dried, and radio-
activity was quantiﬁed using a scintillation counter (Beckman Coulter,
Brea, CA, USA).
Establishment of a doxycycline-inducible cell line
Pancreatic cancer cells were seeded evenly in a 60 mm dish and
incubated for 12 h to reach ~ 90% conﬂuence. When the cells were
ready for transfection, 2 μl of shTRS or myc-TRS lentiviral particles
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and 3 μl of 10 mg ml− 1 polybrene were supplemented with 2 ml of
complete media and added to the plate. After 16 h of incubation, the
culture media was replaced with 3 ml of fresh complete media
containing 1 μg ml− 1 puromycin and incubated for an additional
48 h. The cells were gradually selected by treating with puromycin
every 48 h. To check the efﬁciency of TRS knockdown or over-
expression, cells were treated with 2.5 μg ml− 1 of doxycycline (Dox)
for the indicated times and immunoblotting was performed. shTRS
was purchased from Dharmacon.
SynTarget software
Correlations between expression levels of MUC1 and TRS with the
survival rates of pancreatic cancer patients were analyzed with
SynTarget Software (http://www.chemoproﬁling.org/cgi-bin/GEO/
cancertarget/web_run_CT.V0.S1.pl) using the publicly available
Gene Expression Omnibus (GEO) data set (GEO data set ID:
TCGA_PAAD).
Tissue microarray
Commercially available tissue microarray sections of human PDACs
(Cat# A307II AccuMax Array) were purchased from ISU ABXIS
(Seoul, Korea) and used according to the manufacturer’s instructions.
Slides were analyzed by bright-ﬁeld microscopy using a Pannoramic
250 1.14 slide scanner and Pannoramic Viewer 1.15 (3DHISTECH,
Budapest, Hungary).
Statistical analysis
Statistical analyses were performed using Prism6 (GraphPad Software,
San Diego, CA, USA). All data values are represented as the mean±
s.e.m., and statistical signiﬁcance is denoted as follows:
NS, Not signiﬁcant, P⩾ 0.05; *Po0.05; **Po0.01; ***Po0.001;
****Po0.0001.
RESULTS
Threonine deprivation reduces MUC1 levels in pancreatic
cancer cells
Since previous reports have shown that de novo synthesis of
mucin is sensitive to threonine concentration,13–17 we hypothe-
sized that MUC1 would be affected by threonine levels in
pancreatic cancer cells. Thus, we examined whether MUC1 is
more sensitive to the level of threonine than other amino acids
in the media. The removal of threonine (Thr− ), but not
phenylalanine (Phe− ), valine (Val− ) or tryptophan (Trp− )
signiﬁcantly reduced MUC1 and MUC1-CT at the protein level
(Figure 1a). However, no changes in MUC1 mRNA level were
observed in Panc 10.05 cells in which threonine was deprived
(Figure 1b). Next, the time-dependent change in MUC1 levels
after the deprivation of threonine was investigated. When Panc
10.05 cells were incubated in threonine-free media, cellular
levels of MUC1 and MUC1-CT were reduced in a time-
dependent manner (Figure 1c) but mRNA levels of MUC1
were not changed under the same conditions (Figure 1d). To
examine whether threonine depletion affects global translation
or only the level of MUC1, a [35S]-Met incorporation assay was
performed during threonine deprivation. Threonine depriva-
tion had no time-dependent effect on global protein synthesis,
whereas signiﬁcant inhibition of MUC1 levels was observed
under the same conditions. Cycloheximide (CHX), known as a
protein translation inhibitor, completely blocked de novo
protein synthesis22 (Figure 1e). After withdrawal of threonine
for 2 h, threonine was re-added for 1 h (Thr− /+) or 2 h
(Thr− /++) to Panc 10.05 cells, resulting in the restoration of
the MUC1 and MUC1-CT level, further supporting the effect
of threonine on MUC1 (Figure 1f). In the course of these
experiments, MUC1 protein levels were rapidly reduced in the
absence of threonine. To further characterize this observation,
MUC1 protein stability was measured after blocking de novo
protein synthesis with CHX, and found that the half-life of
MUC1, as well as MUC1-CT, was shorter than 1.5 h
(Figure 1g). These results suggest that MUC1 would need
active biosynthesis to maintain its steady-state cellular level. In
addition, the dependence of MUC1 on threonine in other
pancreatic cancer cells was examined. The results showed a
decrease in protein levels of MUC1 and MUC1-CT during the
starvation of threonine in AsPC-1 and BxPC-3 cells
(Figure 1h). Taken together, cancer-associated overexpression
of MUC1 would highly increase the demands on the cellular
supply of threonine.
Threonine deprivation suppresses pancreatic cancer cell
migration
It is known that MUC1 contributes to cancer cell
migration.23–25 To verify the effect of threonine in MUC1-
expressing pancreatic cancer cells, experiments that assessed the
migration of pancreatic cancer cells following starvation of
amino acids were performed. While migration of Panc 10.05
Figure 2 Effects of threonine deprivation on pancreatic cancer cell migration. (a) Panc 10.05 cells were seeded at equal densities into
96-well plates, cultured to conﬂuency, mechanically wounded by scratching, incubated in each medium and then monitored for 24 h by
IncuCyte Zoom. The data is displayed as line graphs. (b) Quantiﬁcation of migration of Panc 10.05 cells treated as described in (a) for
24 h. Migration distances were measured using the IncuCyte software and displayed as a bar graph. (c) Panc 10.05 cells were seeded at
equal densities into 96-well plates, imaged within the IncuCyte Zoom, and analyzed as percentage conﬂuent. The data is displayed as a
bar graph. (d and e) Quantiﬁcation of the migration of AsPC-1 (d) and BxPC-3 (e) cells treated as described in a for 24 h. Migration
distance was measured using the IncuCyte software and displayed as a bar graph. (f) Panc 10.05 cells were transfected with non-targeting
or MUC1 targeting siRNAs for 24 h and then incubated in media with or without threonine for 24 h. Protein levels of MUC1 and TRS were
monitored by immunoblotting with the respective antibody. (g) Panc 10.05 cells were seeded at equal densities into 96-well plates,
cultured to conﬂuency, mechanically wounded by scratching, incubated in medium with or without threonine and then monitored for 24 h
by IncuCyte Zoom. Cell migration was quantiﬁed based on the distance separating wound images and displayed as a bar graph.
(a–e and g) *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001; NS, not signiﬁcant vs control group. Values represent means± s.e.m. of
three independent experiments.
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Figure 3 MUC1 biosynthesis via TRS in pancreatic cancer cells. (a) TRS was suppressed with two different siRNAs for 48 h in Panc 10.05
cells and protein levels of MUC1 and MUC1-CT were evaluated by immunoblotting with anti-MUC1 antibody. AlaRS and tubulin were used
as controls. siCON, non-targeting control siRNA. (b) Effects of TRS suppression on the transcription levels of MUC1 and TRS were
analyzed by qRT–PCR with primers targeting TRS and MUC1. (c) TRS and AlaRS were suppressed with their speciﬁc siRNAs for 48 h in
Panc 10.05 cells, and protein levels of MUC1 and MUC1-CT were evaluated by immunoblotting with an anti-MUC1 antibody (top) and
displayed as a bar graph (bottom). (d) TRS and AlaRS were suppressed with their speciﬁc siRNAs for 48 h in Panc 10.05 cells and
treated with puromycin (1 μM) for 30 min. De novo global protein synthesis was then monitored by immunoblotting of cell lysates with an
anti-puromycin antibody. The protein levels were quantiﬁed by Ponceau S staining. CHX was employed as a positive control to block de
novo protein synthesis (top).The ratio of de novo protein synthesis versus global protein synthesis was determined as a percentage and
shown as a bar graph (bottom). (e) Panc 10.05 cells were transfected with siRNAs against TRS, AlaRS, or a non-targeting control, and the
catalytic activities of cell lysates were determined by threonylation of tRNAThr as described in the Methods. The amount of threonine-
charged tRNAs was measured by scintillation counting and the data was displayed as a bar graph. (f) Panc 10.05 cells were transfected
with siTRS or siAlaRS for the indicated times, and the protein levels of TRS and AlaRS were evaluated by immunoblotting using anti-TRS
or anti-AlaRS antibodies. CHX was used as a positive control and treated for 30 min. (g) Protein synthesis was measured in Panc 10.05
cells transfected with siCON, siTRS, or siAlaRS for the indicated times by [35S]-Met incorporation assay. Data is displayed as a bar graph.
CHX was used as a positive control and treated for 30 min. (h) Panc 10.05 and AsPC-1 cells that expressed inducible shRNA-targeting
TRS were cultured in the presence or in the absence of Doxycycline (Dox) for 24 to 48 h. Expression levels of MUC1, MUC1-CT and TRS
were determined by immunoblotting using anti-MUC1 or anti-TRS antibodies. (i) MIA PaCa-2 and PANC-1 cells that expressed inducible
myc-tagged TRS were cultured in the presence or absence of Dox for 24 to 48 h. Expression of MUC1, MUC1-CT, and myc-tagged TRS
were detected by immunoblotting with each respective antibody. (b–e and g) **Po0.01; ***Po0.001; ****Po0.0001; NS, not
signiﬁcant vs control group. Values represent means± s.e.m. of three independent experiments.
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cells was signiﬁcantly diminished by starvation of total amino
acids, threonine displayed the highest sensitivity among single
amino acid depletion (Figures 2a and b). In this experimental
condition, cell growth was minimally affected (Figure 2d).
Migration of other MUC1-expressing pancreatic cancer cells,
AsPC-1 (Figure 2d) and BxPC-3 (Figure 2e) was also reduced
in the absence of threonine. To evaluate whether the reduction
in migration by threonine deprivation is dependent on MUC1
level, Panc 10.05 cells were transfected with siMUC1, and
incubated in threonine-free media. The protein levels of MUC1
and MUC1CT were decreased by threonine deprivation or
siMUC1 treatment (Figure 2f). Knockdown of MUC1
decreased migration of Panc 10.05 cells and showed little effect
on migration in the absence of threonine (Figure 2g), indicat-
ing that the threonine-mediated decrease in migration is
dependent on MUC1. Taken together, these results demon-
strate that threonine deprivation suppresses the migration of
pancreatic cancer cells expressing MUC1.
TRS regulates MUC1 biosynthesis
Since TRS catalyzes the ligation of threonine to its substrate
tRNA for incorporation into nascently synthesized proteins, the
inhibition of TRS catalytic activity or its expression can reduce
MUC1 biosynthesis. To assess this possibility, TRS expression
was suppressed using its speciﬁc siRNAs and checked whether
it would affect the cellular level of MUC1. To improve
experimental validation, two different siRNAs targeting differ-
ent regions of human TRS were utilized. Both of the siRNAs
targeting TRS appeared to signiﬁcantly reduce MUC1 and
MUC1-CT levels when compared to non-targeting siRNA
(Figure 3a). There were no changes observed in MUC1 mRNA
under the same conditions (Figure 3b). To determine the TRS
dependence on MUC1 levels, we transfected siRNA targeting
TRS or alanyl-tRNA synthetase (AlaRS) into Panc 10.05 cells
and found a speciﬁc reduction of MUC1 and MUC1-CT levels
in cells treated with siTRS, but not with siAlaRS (Figure 3c).
The next step was to examine how the suppression of TRS or
AlaRS would affect global protein synthesis using a SUnSET
technique20 since they are protein synthesis enzymes. For this
approach, Panc 10.05 cells transfected with siRNA were
incubated with a low dose of puromycin (1 μM), which was
incorporated into newly synthesized polypeptide chains. Newly
synthesized proteins labelled with puromycin were quantiﬁed
by immunoblotting of the whole cell lysates. The results
showed no changes among siCON-, siTRS- and siAlaRS-
treated cells in the amounts of newly synthesized proteins
while CHX treatment completely blocked de novo protein
synthesis (Figure 3d). In this condition, threonylation activity
was only decreased in the cells transfected with siTRS, but not
with siAlaRS (Figure 3e). It was also important to evaluate total
protein synthesis at different times (24, 48 and 72 h) after the
transfection of siRNAs using the [35S]-Met incorporation assay.
The protein levels of TRS and AlaRS were decreased in the
siRNA-treated cells (Figure 3f), but global protein synthesis was
not signiﬁcantly impacted despite the reduction in TRS or
AlaRS protein levels (Figure 3g). These results indicate that
suppression of TRS speciﬁcally reduced biosynthesis of
threonine-rich MUC1 without affecting global protein synth-
esis. To evaluate the effects of TRS on the MUC1 protein level,
two types of pancreatic cancer cells were generated expressing
TRS shRNA or Myc-tagged TRS induced by doxycycline (Dox).
To induce the target genes, pancreatic cancer cells were
Figure 3 Continued.
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Figure 4 Effects of TRS inhibitors on pancreatic cancer cell migration. (a) Aminoacylation activity of a recombinant human TRS protein
was assayed with ThrAMS titration (10–10 000 nM), with an estimated IC50 of 245 nM. The activity was normalized to DMSO, which was
used as the solvent for ThrAMS. ThrAMS, 5′-O-(N-(L-threonyl)-sulfamoyl) adenosine; BN, Borrelidin. (b) Panc 10.05 and AsPc-1 cells were
treated with the indicated concentration (10 and 100 nM) of BN for 4 h. Protein levels of MUC1, MUC1-CT and TRS were monitored by
immunoblotting with each respective antibody. (c) Panc 10.05 and AsPC-1 cells were treated with the indicated concentration (1 and
10 μM) of ThrAMS for 4 h. Protein levels of MUC1, MUC1-CT and TRS were monitored by immunoblotting with each antibody. (d) Panc
10.05 cells were seeded at equal densities into 96-well plates, cultured to conﬂuency, mechanically wounded by scratching, incubated in
medium with the indicated concentrations (10 nM to 1 μM) of BN and then monitored for 12 h by IncuCyte Zoom. Cell migration was
quantiﬁed based on the distance separating wound images and displayed as a bar graph. (e) Panc 10.05 cells were seeded at equal
densities into 96-well plates, cultured to conﬂuency, mechanically wounded by scratching, incubated in medium with the indicated
concentrations (1 to 100 μM) of ThrAMS and then monitored for 12 h by IncuCyte Zoom. Cell migration was quantiﬁed based on the
distance separating wound images and displayed as a bar graph. (f) Panc 10.05 cells were seeded at equal densities into 96-well plates
with the indicated concentrations (10 nM to 1 μM) of BN and imaged within the IncuCyte Zoom. Proliferation was analyzed as the
percentage conﬂuent and displayed as a bar graph. (g) Panc 10.05 cells were seeded at equal densities into 96-well plates with the
indicated concentrations (1 to 100 μM) of ThrAMS and imaged within the IncuCyte Zoom. Proliferation was analyzed as the percentage
conﬂuent and displayed as a bar graph. (d–g) *Po0.05; ***Po0.001; ****Po0.0001; NS, not signiﬁcant vs control group. Values
represent means± s.e.m. of three independent experiments.
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incubated with Dox (10 ng ml− 1) for 24 h. The silencing of
TRS following Dox treatment resulted in a marked decrease in
the levels of MUC1 and MUC1-CT in Panc 10.05 and AsPC-1
cells (Figure 3h). On the other hand, overexpression of TRS by
Dox induction resulted in a signiﬁcant increase in the level of
MUC1 and MUC1-CT in MIA PaCa2 and PANC-1 cells
(Figure 3i). These data suggest that TRS speciﬁcally regulates
the biosynthesis of MUC1.
TRS inhibitors suppress pancreatic cancer cell migration
Next, we investigated whether the inhibition of TRS catalytic
activity would also affect MUC1 level. For this study, we
inhibited the TRS activity with the macrolide antibiotic,
borrelidin (BN), a potent non-competitive inhibitor of TRS,
and 5′-O-(N-(L-threonyl)-sulfamoyl)-adenosine (ThrAMS), a
non-hydrolyzable analog of the reaction intermediate,
threonyl-adenylate. In the aminoacylation assay with human
TRS, activity was decreased by ThrAMS treatment in a dose-
dependent manner with an estimated IC50 of 245 nM
(Figure 4a, left). Previous studies have shown that BN inhibits
the threonine activation step of human TRS with an inhibition
constant (Ki) value of ~ 7 nM (Figure 4a, right).21 Panc 10.05
and AsPC-1 cells were then treated with different doses of BN
and ThrAMS to investigate the effects on MUC1 levels by
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western blotting. The results showed a dose-dependent
decrease of MUC1 and MUC1-CT levels in these cells
(Figures 4b and c). To see whether TRS inhibitors would
affect the growth and migration of pancreatic cancer cells, cell
growth and wound-healing assays were performed. When Panc
10.05 cells were treated with different doses of BN or ThrAMS
for 12 h, both BN and ThrAMS dramatically inhibited cell
migration (Figures 4d and e), with little effect on cell growth
(Figures 4f and g). Collectively, these results suggest the
signiﬁcance of TRS activity for biosynthesis of the
protein MUC1.
TRS affects pancreatic cancer cell migration
We next sought to utilize the two Dox-inducible TRS knock-
down and overexpression cell lines that were used above to
conﬁrm that TRS-dependent MUC1 synthesis would affect
pancreatic cancer cell migration. MUC1 and MUC1-CT
protein levels were signiﬁcantly reduced 24 h after TRS
suppression (Figure 5a). Unsurprisingly, treatment of siRNA
targeting MUC1 in shTRS-induced Panc 10.05 cells also
decreased MUC1 and MUC1-CT protein levels (Figure 5a).
Interestingly, suppression of either TRS or MUC1 decreased
Panc 10.05 cell migration to similar extents (Figures 5b and c),
with little effect on cell growth (Figure 5f). On the contrary,
there was an observed increase in MUC1 and MUC1-CT levels,
following induction of Myc-TRS but not when MUC1 was
suppressed with its speciﬁc siRNA (Figure 5e). MIA PaCa-2
cell migration was increased when Myc-TRS was induced, but
decreased after treatment with siMUC1 (Figures 5f and g)
without affecting cell growth (Figure 5h). Taken together,
our data indicate that TRS could affect pancreatic
cancer cell migration by regulating protein levels
of MUC1.
TRS and MUC1 levels are positively correlated with
pancreatic cancer
The next step was to understand whether expression of TRS
and MUC1 would show any relevance to the survival of
pancreatic cancer patients. This required bioinformatics analy-
sis using SynTarget, a new online tool that investigates the
expression of multiples genes from microarray datasets for
synergistic survival relationships (Figure 6a).26,27 Interestingly,
co-expression of TRS and MUC1 at high levels showed a
positive correlation with poor survival outcomes of the patients
(Figure 6b). On the contrary, when the expression levels of
both TRS and MUC1 were low, patient survival was signiﬁ-
cantly improved (Figure 6c). To further assess the correlation
between MUC1 and TRS levels in clinical pancreatic tumors, it
was important to analyze the tissue levels of the two proteins
using a tumor microarray (TMA) including 30 clinical
pancreatic tumor samples. Immunohistochemical signals of
MUC1 and TRS were scored according to staining intensity,
and it was found that tissue samples with high levels of both
TRS and MUC1 accounted for 60% of the total tissue samples.
(Figure 6d). Moreover, strong staining of MUC1 and TRS was
observed in the duct region of tumor samples, whereas no
staining was observed in the duct region of normal samples
(Figure 6e). These results support the hypothesis that
higher expression of TRS would increase the MUC1 level,
contributing to the poor survival of pancreatic cancer
patients.
DISCUSSION
The oncoprotein MUC1 is overexpressed in 90% of pancreatic
cancers and associated with a short survival rate.28,29 MUC1
also induces epithelial-mesenchymal transition, as well as
increased cell invasion.30 For these reasons, MUC1 is con-
sidered an attractive therapeutic target to moderate pancreatic
cancer progression. In this study, deprivation of threonine
(Figure 1), and reduction of TRS expression (Figure 3) and
TRS catalytic activity (Figure 4) were associated with decreased
MUC1 levels, and consequently, the suppression of pancreatic
cancer cell migration. A number of preclinical studies suggest
that decreasing mucin expression in tumors has potential as a
novel molecular approach for the treatment of pancreatic
cancer.31–34 Since MUC4 and MUC16 are also threonine-rich
Figure 5 Effects of TRS on pancreatic cancer cell migration. (a–d) Panc 10.05 cells were transfected with non-targeting or MUC1
targeting siRNAs for 24 h and then treated with Dox for 24 h to induce shRNA speciﬁc to TRS. (a) Protein levels of MUC1 and TRS were
monitored by immunoblotting with each respective antibody. (b) Panc 10.05 cells were seeded at equal densities into 96-well plates,
cultured to conﬂuency, mechanically wounded by scratching, incubated in medium and then monitored for 24 h by IncuCyte Zoom. Cell
migration was quantiﬁed based on the distance separating wound images and displayed as a bar graph. (c) Light microscopy images
depicting migration in wound-healing assays as described in (b). Images were captured at 0 h (top) and 24 h (bottom), and showed the
wound gap ﬁlled by cells after scratching. (d) Panc 10.05 cells were seeded at equal densities into 96-well plates and imaged within the
IncuCyte Zoom. Proliferation was analyzed as the percentage conﬂuent and displayed as a bar graph. (e–h) MIA PaCa-2 cells were
transfected with non-targeting or MUC1 targeting siRNAs for 24 h and then treated with Dox for 24 h to induce myc-tagged TRS.
(e) Protein levels of MUC1 and TRS were monitored by immunoblotting with each respective antibody. (f) MIA PaCa-2 cells were seeded at
equal densities into 96-well plates, cultured to conﬂuency, mechanically wounded by scratching, incubated in medium and then monitored
for 24 h by IncuCyte Zoom. Cell migration was quantiﬁed based on the distance separating wound images and displayed as a bar graph.
(g) Light microscopy images depicting migration in wound-healing assays as described in (f). Images were captured at 0 h (top) and 24 h
(bottom), and showed the wound gap ﬁlled by cells after scratching. (h) MIA PaCa-2 cells were seeded at equal densities into 96-well
plates and imaged within the IncuCyte Zoom. Proliferation was analyzed as the percentage conﬂuent and displayed as a bar graph. (b–d
and f–h) *Po0.05; **Po0.01; ****Po0.0001; NS, not signiﬁcant vs control group. Values represent means± s.e.m. of three
independent experiments. All images were captured by IncuCyte Zoom.
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glycoproteins, their cellular levels are also presumably regulated
by TRS in pancreatic cancer cells.35–38
Previous reports showed that threonine is considered an
essential amino acid that is important for mucin synthesis.13–17
In line with these previous studies, the work presented
here indicates that threonine supplementation is critical for
MUC1 oncoprotein biosynthesis in pancreatic cancer cells
(Figure 1).
Many reports have shown the functional implications of
human aminoacyl-tRNA synthetases (ARSs) in cancer growth
and progression via their unique activities other than their
catalytic activities.39–42 However, it is unknown whether the
increased expression of ARSs would catalytically contribute to
tumorigenesis. Presented in this study is the ﬁrst report
showing that the biosynthesis of mucin can be controlled
either by the inhibition of TRS activity or by the suppression of
Figure 6 Positive correlation between MUC1 and TRS in pancreatic cancer. (a) Positive correlation between MUC1/TRS co-expression and
reduced survival of pancreatic cancer patients based on the dataset from TCGA. (GEO dataset ID: TCGA_PAAD). (b and c) The
bioinformatics analysis of synergistic effects of MUC1 and TRS co-expression on overall survival in months within human pancreatic
adenocarcinoma patients with (b) high MUC1 and high TRS expression (**Po0.01) or (c) with low MUC1 and low TRS expression
(*Po0.05). (d) Summary table of the quantitative expression of MUC1 and TRS with the score of the respective pancreatic
adenocarcinoma tissue microarray (TMA). A TMA of pancreatic adenocarcinomas was immunostained with antibodies against MUC1 and
TRS, respectively. Immunohistochemical (IHC) signals were scored by the staining intensity (0: no signal, 1: weak signal, 2: intermediate
signal and 3: strong signal). Low, 0–1; high, 2–3. (e) Representative examples of patient biopsies of pancreatic adenocarcinoma
assembled into a TMA stained for MUC1 and TRS, depicting the reciprocal expression pattern (×5 magniﬁcation) (top). Boxed areas are
shown at higher magniﬁcation (×20) (bottom). Scale bar (×5), 500 μm; scale bar (×20), 100 μm.
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TRS expression without affecting global protein synthesis. TRS
expression has been shown to be increased in ovarian cancer
and was suggested to be associated with angiogenesis.43
However, it may be more related to the unique activity of
the secreted TRS in the extracellular space, as it was previously
shown that TRS can be secreted to promote angiogenesis.44
Considering that TRS speciﬁcally regulates the biosynthesis of
the threonine-rich protein MUC1, it would be interesting to
investigate whether speciﬁc amino acid-rich proteins can also
be speciﬁcally regulated by their cognate ARSs.
ARSs are validated drug targets against pathogens.45,46
Recently, there have been increasing efforts to target human
ARSs for various pharmacological indications.47,48 For instance,
halofuginone (HF), the halogenated derivative of febrifugine,
has been tested for ﬁbrosis treatment.49 The accumulation of
extra-cellular matrix proteins, especially collagen, is a major
feature of ﬁbrotic disease. Since collagen is a proline-rich
protein, prolyl-tRNA synthetase (PRS) could serve as a
preferred target to block collagen biosynthesis. In fact, HF, a
speciﬁc PRS inhibitor, showed high efﬁcacy in decreasing
collagen levels.50,51
In summary, this study provides evidence illuminating the
potential role of TRS in the migration of human pancreatic
cancer cells by enhancing MUC1 biosynthesis. The effect of
TRS inhibitors on MUC1 levels and cancer cell migration
suggests the possibility targeting of TRS as a novel therapeutic
avenue against pancreatic cancer. Further validation studies are
currently under way using in vivo models and patient analysis.
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